Xingmeng Biotechnology, invested by Sinovac, has released a new anti rabies drug, covering the entire rabies window period
2024-08-06
On August 4th, the Infectious Disease Prevention and Control Technology Innovation Seminar, hosted by the Beijing Integrative Medicine Society and co organized by Xingmeng Biomedical (Suzhou) Co., Ltd. (hereinafter referred to as "Xingmeng Biotechnology"), was held in Beijing. This seminar discussed the current development status of rabies worldwide, shared the latest prevention and control technologies, and exchanged professional knowledge on how to quickly and correctly handle difficult rabies patients. More than 200 experts and medical workers from the field of infectious disease prevention and control across the country attended the seminar. Rabies is a highly contagious zoonotic disease with a mortality rate close to 100%, but it can be avoided 100% through standardized post exposure management (PEP). On June 12, 2024, the first anti rabies cocktail monoclonal antibody preparation developed by Xingmeng Biotechnology, which complies with WHO recommendations - Zemeloweimazoruvir monoclonal antibody - Kribi, has been approved for market in China. This product is a Class I innovative drug with dual targets, wider spectrum, fast onset, early protection, easy injection, and mild response, making it a new choice for passive immunization against rabies. Technological innovation has always been an important engine for promoting the prevention and control of infectious diseases. Vice President Du Guangqing and Executive Vice President Du Yahong of the Beijing Society of Integrative Medicine both emphasized this viewpoint in their speeches. I hope to continuously improve and optimize rabies prevention and control strategies and measures through this exchange and discussion, establish close cooperative relationships with more experts, scholars, enterprises, and various sectors of society, and jointly promote the development of rabies prevention and control work. The progress of human society is closely related to the prevention and control of infectious diseases. Wang Yu, Chairman of the China Hepatitis Prevention and Control Foundation, shared the development trends and technological innovations in disease prevention and control at home and abroad under the theme of "Dealing with Infectious Diseases: Progress and Challenges". Wang Yu emphasized that humans are facing the threat of numerous pathogenic microorganisms, and only a few have vaccines to deal with them. Immunoglobulin and monoclonal antibodies are allies of vaccines, with significant complementary functions. With the help of biomedical technology, there is an urgent need to develop more preventive antibodies against infectious diseases, while therapeutic antibodies also have broad application prospects. Antibody drugs are playing an important role in both infectious and chronic diseases. Professor Wang Xiangxi, a researcher in the Institute of Biophysics of the Research Institute of the Chinese Academy of Sciences and president of the Joint Research Institute of Science and Technology, said that the development of highly competitive "good" antibody drugs not only requires mastering "new technologies", but also requires in-depth understanding of pathogen evolution and disease. He pointed out that by comprehensively focusing on the neutralizing efficacy of antibodies, the proportion of immune background antibody lineages in the current population, and the evolution of viruses, rational selection of antibody types with high activity and low lineage proportion as drug development targets can minimize the risk of escape by mutant strains. Kribi is such a highly competitive antibody drug that obtained the drug registration approval from the National Medical Products Administration on June 12, 2024, and was officially approved for passive immunization and prevention of adult rabies virus exposure. I am delighted to announce that in 2023, Sinovac has completed its investment in Xingmeng, marking the official alliance between Sinovac and Xingmeng Cao Yifu, CEO of Xingmeng Biotechnology, reviewed the research and development process of Kribi at the meeting. He stated that Kribi's approval marks a breakthrough for Xingmeng Biotechnology in the field of monoclonal antibodies against rabies virus. Kribi has not only gained wide recognition domestically, but its global clinical research results have also proven its excellent efficacy and safety, becoming a new choice for passive immunization against rabies worldwide, and fully promoting the goal of "zero dog to dog transmission of rabies" by 2030. Professor Yin Wenwu, Chief Physician of the Infectious Disease Management Department of the Chinese Center for Disease Control and Prevention and Vice President of the Animal Injury Treatment Branch of the Chinese Medical Rescue Association, introduced at the meeting that China has achieved significant results in rabies prevention and control. This achievement is due to the continuous optimization of rabies prevention and control strategies since the founding of the country, as well as the joint efforts of all parties. China should adhere to the joint prevention and control mechanism for rabies prevention and control, and further standardize the prevention and treatment of rabies exposure. In the latest "Guidelines for Rabies Exposure and Disposal Work", wound disposal measures have been optimized, vaccination procedures have been implemented, regulations on the use of anti rabies monoclonal antibodies have been added to passive immune preparations, the scope of high-risk individuals for rabies exposure has been expanded, and outpatient management for rabies prevention and disposal has been established. Professor Wang Chuanlin, Deputy Director of the Emergency Surgery/Trauma Treatment Center at Peking University People's Hospital and President of the Animal Injury Treatment Branch of the Chinese Medical Rescue Association, stated that the goal of post exposure treatment for rabies is to completely eliminate the rabies virus. Firstly, it is necessary to minimize the virus content in the wound, and passive immune preparations are an important part of post exposure treatment. With the development of technology, monoclonal antibodies have emerged in recent years, which is the direction of passive immunization for rabies. The recently approved cocktail monoclonal antibodies provide more options for clinical PEP. Dr. Liu Xiaoqiang, Chief Physician of Yunnan Provincial Center for Disease Control and Prevention, pointed out in the report "Interpretation of the Phase III Clinical Study of Zemelovir Mazoruvir Monoclonal Antibody" that the Phase III clinical trial of Zemelovir Mazoruvir Monoclonal Antibody is the first main endpoint designed to be the geometric mean concentration (RVNA GMC) of neutralizing antibodies against rabies virus on day 8, which is superior to the human rabies immunoglobulin (HRIG) control group. Zemeloweimazoruvir monoclonal antibody can quickly achieve the required level of protection for the body's RVNA GMC after administration, effectively exerting the immediate neutralizing effect of passive immune preparations on rabies virus and covering the entire rabies window period. In terms of safety, the incidence of drug-related adverse events and serious adverse events of Zemeloweimazoruvir monoclonal antibody was lower than that of the HRIG group. The conference invited Chen Qingjun, Chief Physician of the Emergency Department of Beijing Chaoyang Hospital, and Liu Si, Deputy Director of the Emergency Department of Peking University First Hospital, as the conference hosts. In addition, more than 100 experts from infectious disease prevention and control related fields from across the country attended the meeting and highly praised the safety and effectiveness of Kribi. Du Yahong and Du Guangqing, Executive Vice President and Vice President of the Beijing Integrative Medicine Society, Wang Yu, Chairman of the China Hepatitis Prevention and Control Foundation and former Director of the Chinese Center for Disease Control and Prevention, Yin Weidong, Chairman, President and CEO of SINOVAC, and Cao Yifu, Founder and CEO of Xingmeng Biotechnology, attended the meeting. (New Society)
Edit：HAN ZHUOLING Responsible editor：CAICAI
Source：xinhuanet
Special statement: if the pictures and texts reproduced or quoted on this site infringe your legitimate rights and interests, please contact this site, and this site will correct and delete them in time. For copyright issues and website cooperation, please contact through outlook new era email：lwxsd@liaowanghn.com
Recommended Reading Change it 
Home
